Additionally, functional studies—such as patient-derived organoids and single-cell sequencing—are essential to elucidate the biological impact of SMAD2, ERBB4, ALK, and CTNNB1 mutations and their roles in tumor heterogeneity, drug resistance, and immune evasion. This evidence concerns the gene SMAD2 and neoplasm.